Get started

PFE

Pfizer | Fundamental Analysis | Short view Many would agree that a half victory is better than a total defeat. Pfizer and BioNTech have seen this through firsthand experience. The two partners had hoped that an FDA advisory committee would recommend revaccination with the COVID-19 vaccine to all Americans 16 years of age and older. A week ago, however, the committee voted 16-2 against recommending the Pfizer-BioNTech vaccine for a wide age range. It wasn't just bad news for these drug companies, however. The FDA advisory committee also voted unanimously to recommend the boosters for U.S. citizens age 65 and older, and anyone at high risk for severe COVID-19. And now you're probably wondering, could Pfizer stock be a reasonable investment choice after this partial victory? The FDA still has to decide whether to revaccinate the Pfizer-BioNTech vaccine. If the agency follows the commission's recommendations and the Centers for Disease Control and Prevention (CDC) agrees with them, many additional vaccines could soon become available. As per the U.S. Department of Health and Human Services' Office on Aging, there were about 52.4 million Americans age 65 and older in 2018. Today, that number is undoubtedly higher. Vaccination rates among older Americans are higher than any other age group. According to the CDC, nearly 85 percent of people between the ages of 65 and 74 have been fully vaccinated. Nearly 80% of Americans age 75 and older have been fully vaccinated. We don't know how many of these people received the Comirnaty COVID-19 vaccine from Pfizer and BioNTech. However, overall, Comirnaty accounts for about 57% of all COVID-19 vaccine doses administered to date. It is estimated that about 25 million Comirnaty revaccinations could be administered in the following months if the FDA and CDC give the green light to revaccination. Based on previous vaccine prices, the total cost of revaccination for the groups recommended by the FDA panel could approach $500 million. At first glance, the possibility of an additional $500 million over the next few months may seem significant. However, there are several reasons not to get so excited. Most importantly, none of the companies are likely to get "extra" money from boosters shortly. The U.S. has already ordered a total of 500 million doses from Pfizer and BioNTech, plus another 500 million doses for transfer to other countries. At least at this time, it is doubtful that extra doses will be purchased by the government to vaccinate Americans. Keep in mind also that Pfizer and BioNTech share profits from Comirnaty. Even if the companies could expect additional orders from the U.S. government for boosters, the financial impact for Pfizer would not be huge. In the second quarter, the company had revenue of $19 billion and profits of nearly $5.6 billion. There is really no good reason to buy Pfizer stock based on the recommendation of the FDA advisory committee. Nevertheless, there are other reasons why investors might seriously consider stock in this major pharmaceutical company. The need for an annual refill for everyone is still a real possibility. If Pfizer can count on strong recurring revenues from Comirnaty for years to come, the stock will look much more attractive. No doubt, Pfizer doesn't just rely on its COVID-19 vaccine. The pharmaceutical giant has other growth drivers that should appeal to investors, notably the rare heart disease drug Vyndaqel/Vyndamax and the blood-thinning drug Eliquis. Pfizer's pipeline could bring even more big wins. A pill for COVID-19 may be on the way. The drugmaker also has more than 20 other late-stage programs. It is also adding to its portfolio through deals, including intentions to buy Trillium Therapeutics. Last, but not least, is Pfizer's dividend. Many income investors will like the dividend yield, which is currently 3.5%. For some investors, Pfizer stock looks like a good choice. But any endorsement for older Americans boosters isn't much of a factor in deciding whether or not to buy the stock one way or the other.
PShort
by FOREXN1
3
AMD, MRNA, PFE after WSB play finished..!I reviewed WSB's plays in different articles and explained their price manipulation system Look at their most famous plays after few weeks will make it obvious that sharp rising price has no chance of reoccurring without the same manipulation. I believe there will be no push from WSB soon! It seems after the last Flash crash in the crypto market, they are not able to handle anything above the 100 Billion dollar market cap! For me, there is a very big question: How should we interpret the charts??? I suggest doing the analysis based on the most recent part and try to be aware of the reality that not all prices will repeat in the future! reading my previous articles about WSB could help you consider this factor in your trading!
NASDAQ:AMD
by Moshkelgosha
Pfizer dropping momentumFibgoals fractally at origin of Wave 5 of impulse and then beyond. If our mapping is correct, this impulse is done for now. Remember, this is not financial advice. You must do your own research and carefully make decisions for yourself by yourself. We love TA and do not provide individually tailored financial advice, or financial advice period. Now that aside, Fibonacci in crystal clear green and invalidation noted, as always, in red. Good luck out there.
NYSE:PFEShort
by Rykin_Capital
PFE Daily TimeframeSNIPER STRATEGY (new version) It works ALMOST ON ANY CHART. It produces Weak, Medium and Strong signals based on consisting elements. NOT ALL TARGETS CAN BE ACHIEVED, let's make that clear. TARGETS OR ENTRY PRICES ARE STRONG SUPPORT AND RESISTANCE LEVELS. ENTRY PRICE BLACK COLOR TARGETS GREEN COLOR STOP LOSS RED COLOR DO NOT USE THIS STROTEGY FOR LEVERAGED TRADING. It will not give you the whole wave like any other strategy out there but it will give you a huge part of the wave. The BEST TIMEFRAMES for this strategy are Daily, Weekly and Monthly however it can work on any timeframe. Consider those points and you will have a huge advantage in the market. There is a lot more about this strategy. It can predict possible target and also give you almost exact buy or sell time on the spot. I am developing it even more so stay tuned and start to follow me for more signals and forecasts. START BELIEVING AND GOOD LUCK HADIMOZAYAN
NYSE:PFEShort
by hadimozayan
PFIZER Daily TimeframeSNIPER STRATEGY This magical strategy works like a clock on almost any charts Although I have to say it can’t predict pullbacks, so I do not suggest this strategy for leverage trading. It will not give you the whole wave like any other strategy out there but it will give you huge part of the wave. The best timeframe for this strategy is Daily, Weekly and Monthly however it can work any timeframe above three minutes. Start believing in this strategy because it will reward believers with huge profit. There is a lot more about this strategy. It can predict and also it can give you almost exact buy or sell time on the spot. I am developing it even more so stay tuned and start to follow me for more signals and forecasts.
NYSE:PFEShort
by hadimozayan
2
PFIZER: FUNDAMENTAL ANALYSIS + NEXT TARGET POINT ⚡️As you know, Pfizer's biggest product at the moment is the coronavirus vaccine, Comirnati. The company and its partner BioNTech expect it to bring in more than $33 billion this year. Meanwhile, Pfizer expects revenue from the coronavirus vaccine to account for 42% of the company's total revenue. The vaccine is certainly one good reason to buy stock in this major pharmaceutical giant. But there is another reason to buy Pfizer stock, and it has nothing to do with the COVID-19 vaccine. It is important to remember that Pfizer has a huge number of commercialized products, including seven blockbuster drugs. Earlier this month, one of them received good news - news that should prompt us to take a closer look at this pharmaceutical company's stock. Eliquis, the blood-thinning drug commercialized by Pfizer and its partner Bristol Myers Squibb, received a very important decision in the appeals court. The court upheld the original decision protecting the patents on this best-selling drug, including the drug's composition and formula. This means that the generic drugmaker will not be able to enter the market with a competing drug until April 2028. Pfizer and Bristol Myers will probably file another appeal, but after two courts have already ruled in their favor, one can be optimistic about their case. This is great news for Pfizer, given the revenue generated from the sale of the drug Eliquis. Last year, Pfizer reported more than $4.9 billion in revenue from the alliance and direct sales of the drug Eliquis. That's a 17% increase over the previous year. And this was during a pandemic when access to non-COVID health care was limited. Eliquis continues to be one of Pfizer's biggest drugs. In the second quarter of this year, Eliquis generated more than $1.4 billion in revenue. That's a 16% increase over the previous year, and Eliquis was Pfizer's second-largest drug after the coronavirus vaccine. Of course, generic competition will eventually lead to lower sales of this blockbuster drug. But the court ruling gives Pfizer seven years to develop products that can replace Eliquis as a major source of revenue. Pfizer has a lot of development going on. One of the most interesting candidates is an oral drug to treat the coronavirus. It would be a pill that people could take within days of the first symptoms, and it could be a game-changer and generate billions of dollars in revenue. Pfizer began Phase 2/3 trials in July and plans to present data in the fourth quarter. The company also recently began a Phase 3 trial of a vaccine candidate against respiratory syncytial infection. Currently, there is no vaccine against this common cause of severe respiratory disease. Should you buy Pfizer stock because of news about the Eliquis patent? It's not the only reason to buy the stock, but it's one great reason. Add to that the recurring earnings from the coronavirus program. And let's not forget the company's other blockbusters. Let's not forget the drugs and vaccines that could bring in a lot of revenue in the future. All of this together is a solid recipe for success over time. Pfizer stock is up 25% and is currently outperforming the S&P 500 Index. However, the stock is hardly reflective of all the positives now and in the future. They are trading at 11 times earnings estimates. By that measure, the stock is cheap today. Pfizer stock is far behind biotech players in the coronavirus vaccine space such as its own partner BioNTech and rival Moderna. You can't be sure that the situation will change. It's much easier to quickly raise the price of a company with less market value than a major pharmaceutical player. But over time, Pfizer has serious potential to increase revenues and profits -- and that should match the stock's rise. This month's news on the Eliquis patent is a huge step in the right direction.
NYSE:PFELong
by FOREXN1
4
$PFE - Key Levels and Analysis - REQUEST - I hold no position$PFE - Key Levels and Analysis ————— @Smartdaytrading, I think that PFE is overdue for a trip back toward the 180EMA(Purple)… Right now it is sitting right under the 35 EMA (Red) and this week if it closes under the gray line right under the red then I’d say watch for 41.64… that would be a good place to add if you’re long… The 35EMA has held as support for a large part of this year, but it tends to become resistance once it crosses down (and actually closes with the entire candle under the 35EMA)… and it’s been a little too long since it’s corrected back to the 180… Anything can happen... but I'd say keep a close eye on 41-42 area —————— I am not your financial advisor, but I will happily answer questions and analyze to the best of my ability but ultimately the risk is on you. Red = Resistance Green = Support Blue = trendlines Have fun, y’all!!
NYSE:PFE
by SPYder_QQQueen_Trading
7
PFE STILL MORE GAS IN THE TANKThis chart has been fairly predictable for the past year, however as we start to shape up the larger degree wave count, I've decided to alter this from an expanding diagonal to a typical impulse. The main thing shaping this is the action for wave 2 which appears to be a flat. Under this premise, we have subdivision of wave 3 underway. It appears to be an expanded third: triggering the 1.618 with evidence of another leg up to the 2.272 at $56. This is the primary trade at hand, as we target 15-20% gains here. This trade presents a 10:1 RR with a SL around $45.50 at the recent low for a 20% target. Wave 4 of 3 looks to be complete, hitting the 1.618 extension of A to B (see chart below). We have RSI testing the 70 which will be telling: if it can get into overbought territory, then it's indication of a trend reversal (as markets typically only go into overbought when bullish). Not pictured is the stacking bullish divergence for this wave 4. Another thing that stands out as evidence of wave 4 complete is that it was sharper than wave 2 of 3. By rule of alternation, we would expect this. Upon hitting this target near $56, we will reevaluate, likely close, and look for the next wave down. For now, I have a $45 level identified (w4 larger count) and a 2.618 target near $60 (w5 larger count) on the map. Remember: for extended wave 3s that approach the 2.0, we look for the next fib level near 2.618 for w5. These future targets are dependent on what happens here in this wave 3.
NYSE:PFELong
by warrenbudget
9
This is called WSB effect..!The goal of this article is to explain the Wallstreet Bets methods. I believe all the market participants should be aware of their effects on the market and how they could derail any asset from a normal movement. Let's look at some of their manipulations first: 1- NASDAQ:MVST 2- NASDAQ:WISH 3- NYSE:SPCE 4- NYSE:NIO 5- NASDAQ:FORD 6- NASDAQ:AMD 7- NASDAQ:MRNA 8- NASDAQ:NVDA 9- NASDAQ:TSLA 10- NASDAQ:AAPL 11- NYSE:PFE At this point, you must be able to see the similarities between charts and also group them into 2 different categories! Cluster 1: Small caps Cluster 2: Big caps In cluster 1: they usually target 100% or above In cluster 2: The bigger the market cap of that company the smaller the wave they could push. The big question is Are they predictable? I believe their movement especially on the Topside could be predicted with acceptable accuracy if you know how to monitor their money injection. Let's review some of my published analysis about their plays: August 17, 2021, one day before manipulation ends: NYSE:PFE August 10th, 2021, right at the last day! NASDAQ:MRNA August 4th, right at the last day..! AMD Defining the hypothesis: 1-The Wall Street Bets phenomenon could be a very smart Algorithmic Trading Platform that creates bullish and bearish rallies by smart money injection or withdrawal, and it is not a group of "Apes". 2- Their target prices could be predictable using Option trades data 3- Their pattern of behavior is not Pump and Dump, but it is "Dump-Pump-Dump" 4- Most of their plays were in the ARK Invest's ETFs weeks or months ago. I do not want to make this post very long, so I encourage my followers to read this article and looking at the charts carefully. I will share my findings of WSB in future posts. Moshkelgosha
NASDAQ:MSFTEducation
by Moshkelgosha
42
The S&P 500 $SPX signaling strong divergenceThis probable next correction is very odd. As the index price action is showing strong negative divergence with de ADL and the MACD (one confirming the other), there is no euforia. Is like everyone is expecting this to happen. It may be just lack of interest of the market or that is summer time. The Fear & Greed Index is in extreme fear, that almost never happens on tops. Still I can't ignore the technicals that are at least signaling that the SP:SPX is losing strength. So this is time to manage risk. I'm tightening my stops and suggesting to sell at least part of the positions we have at some of the winners like NYSE:PFE and NASDAQ:GOOG . We opened a short position on the index but I'm still holding some stocks. Also, if the correction actually happens would be a very good opportunity to find strong stocks for the next leg up. I will be looking for strong relative strength and 52 week highs. money.cnn.com
SP:SPXShort
by dpuleo19
4
PFE STRONG AF: All indicators point to continued strong uptrend I REALLY liking PFE rn for long. Here is why ~ Today it not only crossed the VWAP, but it broke the 75th percentile indicating upcoming higher highs. ~ Not only is it riding above the VWAP rn, but there is a nice gap between the price action and SMMA indicating a continued uptrend ~ Price action > 30 EMA > 200 EMA and there is a nice gap between both EMAs. this setup signifies a strong uptrend and an excellent long entry. (especially paired with the fact that the VWAP was crossed) ~ We are maintaining a strong uptrend already on the 50 MA and hourly chart with the 50 MA being a solid support line. I am swinging a PFE call atm (ITM) as PFE is about to be overbought but is not there yet. I believe we may see another test of 50.50 before the pullback. I am hoping we can break it, but if not 50.50 will become a great support zone once we do pass it. I am planning on selling at 50-60 percent profit ( I am at 49 percent rn) and am going to reenter when we retest the VWAP.
NYSE:PFELong
by MathewPiedoux
PFE Uptrend Strong Waiting for pullback to 50 MAPfizer is in a strong uptrend and its hourly keeps coming back to the 50 MA. Each time it has come back to the 50 MA, it has met at a support area. I believe we may see PFE run a bit higher before it returns to the 50 MA as the RSI is undecided (although slightly on a decline). The hourly wicks also do not show any signs of a pullback yet, which supports this idea of a new ATH in the making. I am holding my PFE call until I see some more resistance, but once the tide changes for short term bears I will sell and wait until PFE pulls back to 48.50 (and closes green after touching the 50 MA) before entering calls.
NYSE:PFE
by MathewPiedoux
1
PFIZER INC.:FUNDAMENTAL ANALYSIS+PRICE ACTION|NEXT TARGET|LONG🔔Earlier this month, Pfizer announced promising first-line results from a Phase 2b/3 trial testing the JAK inhibitor ritecitinib for the treatment of alopecia(baldness), suggesting that the drug could finally be approved to treat this autoimmune disease that causes hair loss. But as Jeff Little noted, "The FDA has recently been paying increased attention to the potential side effects of JAK inhibitors, which belong to a family of drugs called DMARDs (disease-modifying anti-rheumatic drugs)." Let's look at the results of the study, what the FDA's concerns mean for this drug and others like it, and whether pharmaceutical giant Pfizer has a chance to make a name for itself in the growing global market for alopecia medications. Pfizer's phase 2b/3 study of the drug ritlecitinib examined the drug's effect on alopecia treatment in a randomized clinical trial involving 719 patients. These patients were 12 years of age or older, had 50% or more scalp hair loss (as measured by the Severity of Alopecia Tool scale, or SALT), and had experienced a current episode lasting six months to 10 years. Pfizer remarked that a clinically meaningful proportion of patients who received 30 mg or 50 mg of ritlecitinib daily achieved less than 20% head hair loss on the SALT scale after 24 weeks of treatment opposed to placebo, consistent with the study's primary efficacy endpoint of improved head hair regrowth. According to Pfizer, the scientific basis for ritlecitinib is that the drug stops the body's immune system from attacking hair follicles, which is thought to contribute to hair loss in patients with alopecia. Despite the study's encouraging results, it's worth noting that ritlecitinib's path to FDA approval for the alopecia indication (or for vitiligo, rheumatoid arthritis, Crohn's disease, and ulcerative colitis, for that matter) will be even more thorough than usual because of its special class of drugs. Ritlecitinib belongs to the class of Janus kinase inhibitors, or JAK inhibitors, which have been under scrutiny by the FDA lately. As per Fierce Pharma, a post-marketing study of Pfizer's JAK-inhibitor Xeljanz revealed serious heart and cancer side effects when the study results were published at the beginning of the year. This urged the FDA to delay the potential approval of the JAK inhibitor back in February while the agency investigates further. Xeljanz was first approved by the FDA in 2012 to treat rheumatoid arthritis, or RA, an autoimmune disease that can cause joint pain and damage throughout the body. The drug was also approved by the FDA in 2017 to treat psoriatic arthritis and in 2018 to treat ulcerative colitis. Although no serious adverse cardiac events or deaths were reported in Pfizer's study of ritlecitinib, it is in this class of drugs. As a result, its future remains very uncertain. If the JAK inhibitor class ultimately withstands increased regulatory scrutiny and the efficacy of ritlecitinib safely treating alopecia persists, the drug could provide a reliable revenue stream for Pfizer. To support this thesis, let's take a look at the global alopecia market and its growth forecast. Pointing to the "increasing prevalence of hair loss" as well as "technological advances in alopecia treatment," Grand View Research believes that the total global alopecia market will grow at an annual rate of 8.1% from $7.6 billion in 2020 to $14.2 billion by 2028. If the alopecia market stays at 35.2% of the total global alopecia market as it was in 2020, Pfizer's total addressable market in this area will be $5 billion by 2028. Given that Pfizer will likely face competition from Concert Pharmaceuticals' JAK inhibitor CTP-543 (first Phase 3 results not expected until 2022) and Eli Lilly and Incyte's JAK inhibitor baricitinib (currently awaiting FDA decision) when it enters the alopecia market, a fragmented market share of 15% is realistic. This would result in $750 million in annual revenue associated with the alopecia drug indications by 2028, which is about 1% of Pfizer's projected 2021 revenue of $78-80 billion. As questions arise about whether JAK inhibitors such as ritlecitinib will be able to gain regulatory approval in the future, it is worth noting that Pfizer does not significantly necessitate that approval to boost earnings in the coming years. In addition to the BNT162b2 COVID-19 vaccine, developed with German company BioNTech, Pfizer also expects to be able to apply for approval in the fourth quarter of this year for the emergency use of the oral antiviral drug COVID-19, known as PF-07321332. Keith Speights thinks this could be a real blockbuster given the huge addressable market, especially since Pfizer won't have to share the profits from oral therapy as it does with BioNTech in the case of BNT162b2. In addition to COVID-19, Pfizer's oncology biosimilars (Ruxience, Zirabev, and Retacrit) tripled their combined sales from $107 million in the second quarter of 2020 to $352 million in the second quarter of 2021, another good catalyst for growth going forward. Nearly half of Pfizer's projected sales this year will come from the $33.5 billion the company expects from its BNT162b2 COVID-19 vaccine (after splitting revenue with a partner, BioNTech). This is based on the 2.1 billion doses the company estimates will be delivered this year. Given sales of the breast cancer drug Ibrance ($1.4 billion through Q2 2021) and the anticoagulant Eliquis ($1.5 billion through Q2 2021), we can assume that these two drugs will also bring in about $3 billion each.
NYSE:PFELong
by FOREXN1
6